Skip to main content
. 2015 Nov 26;7(3):2921–2935. doi: 10.18632/oncotarget.6404

Figure 1. Trastzumab-resistant breast cancer cell lines are significantly insensitive than their parental lines to lapatinib-mediated growth inhibition and apoptosis.

Figure 1

A. SKBR3 and Pool2 or BT474 and HR20 cells were plated onto 96-well plates and incubated at 37°C with 5% CO2. After 24 hr, the culture medium was replaced with 0.1 ml fresh medium containing 0.5% FBS or the same medium containing the indicated concentrations of lapatinib for another 72 hr. The percentages of surviving cells from each cell line relative to controls, defined as 100% survival, were determined by reduction of MTS. Bars, SD. Data show a representative of three independent experiments. B & C. The same cells were untreated or treated with lapatinib (0.1 μmol/L) for 24 hr. Cells were collected and subjected to western blot analyses of PARP (F-PARP, full length PARP; C-PARP, cleaved PARP), caspase-3 (F-Casp-3, full length caspase-3; C-Casp-3, cleaved caspase-3), or β-actin (B); or a specific apoptosis ELISA (C). Bars, SD.